A share price of UroGen Pharma Ltd [URGN] is currently trading at $13.81, up 0.73%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The URGN shares have gain 6.07% over the last week, with a monthly amount glided 87.38%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on June 16, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $50 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on May 22, 2025. On April 16, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $23 on the stock. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on August 22, 2024. Jefferies downgraded its rating to Hold for this stock on February 08, 2023, and downed its price target to $10. In a note dated April 27, 2022, Berenberg initiated an Buy rating and provided a target price of $20 on this stock.
UroGen Pharma Ltd experienced fluctuations in its stock price throughout the past year between $3.42 and $18.15. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $13.81 at the most recent close of the market. An investor can expect a potential return of 70.17% based on the average URGN price forecast.
Analyzing the URGN fundamentals
Trailing Twelve Months sales for UroGen Pharma Ltd [NASDAQ:URGN] were 91.87M which represents 7.84% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -1.47%, and Net Profit Margin reading is -1.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -974.87 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.48 points at the first support level, and at 13.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.22, and for the 2nd resistance point, it is at 14.64.
Ratios To Look Out For
To put it in perspective, the Current Ratio for UroGen Pharma Ltd [NASDAQ:URGN] is 5.65. In addition, the Quick Ratio stands at 5.47 and the Cash Ratio stands at 2.48. Considering the valuation of this stock, the price to sales ratio is 6.93.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Jun 09 ’25 when 5162.0 shares were sold. Officer, Schoenberg Mark completed a deal on Jun 09 ’25 to buy 5162.0 shares. Meanwhile, Chief Medical Officer Schoenberg Mark sold 4551.0 shares on Jan 31 ’25.
